GlaxoSmithKline's head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics.
GlaxoSmithKline's board had responded to the broadside attack delivered by activist investor Elliott Management yesterday, saying it stands firmly behind the leadership of chief executive E
GlaxoSmithKline chief executive Emma Walmsley was no doubt hoping that an upbeat assessment of the firm's prospects at an investor meeting last week would deflect criticism of her leadershi
With the first patient set to receive Biogen's new Alzheimer's drug Aduhelm in Rhode Island today, US consumer advocacy organisation Public Citizen is deeply unhappy about the FDA's approva
Moncef Slaoui has stepped down from positions at three more companies, shortly after being dismissed from a firm owned by GlaxoSmithKline for alleged sexual harassment.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.